STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues

Versant Ventures, Eli Lilly, and a handful of other investors announced Monday that they have poured $100 million into a new startup devoted to solving a gene therapy challenge that has ensnared many well-funded academics and biotechs before it. The company, called Seawolf Therapeutics, is trying to deliver genes to patients without the use of viruses. In addition to the $100 million fundraising, Sanofi has also inked a partnership with the company. Viruses have proven to be powerful gene delivery drones in several rare diseases, and they are being tested in hundreds of trials. But they come with drawbacks. A patient can only ever receive a single dose, after which they develop antibodies against the virus. And at high doses the treatments can have serious side effects. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe

Original Source

Read the full article at Statnews →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.